Australia’s first oral weight-loss medicine now available through private prescriptions
19 Nov 2026
GPs can prescribe the Wegovy pill privately from Friday, following its launch by pharmaceutical company Novo Nordisk.
The launch marks a new development in obesity treatment, as the first oral GLP-1 medicine approved for weight management reaches Australian pharmacies. It comes shortly after rival pharmaceutical company Eli Lilly announced approval of its oral weight-loss medicine, orforglipron, marketed as Foundayo, with prescriptions expected to become available in the coming days.
The growing availability of these medicines follows a sharp rise in GLP-1 use across Australia. A study found that around 500,000 Australians were using GLP-1 medicines last year.
Wegovy pill doses and costs
The Wegovy tablet is available in four strengths:
- 1.5 mg – $260
- 4 mg – $270
- 9 mg – $280
- 25 mg – $395
Treatment starts at the lowest dose, with the dose increased every 30 days until patients reach the recommended maintenance dose of 25 mg, according to Australian product information.
Prices may vary between pharmacies and depending on the services provided.
More treatment choices for patients
Dr Terri-Lynne South, Immediate Past Chair of RACGP Specific Interests Obesity Management, said the arrival of oral weight-loss medicines could encourage more patients to discuss their health and treatment options with their GPs.
She described the new medicine as another option for GPs managing obesity.
Until now, GLP-1 medicines approved for weight management have been available as injections. The introduction of a tablet may help people who are uncomfortable with needles or prefer taking daily medication.
Dr South said having more options would help GPs consider different treatments based on each patient's needs.
Who can use the Wegovy pill?
The Therapeutic Goods Administration (TGA) approved the Wegovy pill in early November.
When used alongside a reduced-calorie diet and increased physical activity, it is approved for long-term weight management in adults with:
- Obesity, with a BMI of 30 kg/m² or above.
- Overweight, with a BMI of 27 kg/m² or above and at least one weight-related health condition.
It is also approved to help reduce the risk of major cardiovascular events in eligible adults with established cardiovascular disease, a BMI of at least 27 kg/m² and no established type 1 or type 2 diabetes.
Important differences between oral treatments
Dr South said GPs need to understand how the two oral medicines differ, particularly when advising patients.
Wegovy contains semaglutide, a peptide medicine. It must be taken on an empty stomach with no more than a small sip of water. Patients must then wait at least 30 minutes before eating, drinking or taking other medicines.
Orforglipron, marketed as Foundayo, is a non-peptide GLP-1 medicine. It does not have the same food and water restrictions, although it can have important interactions with other medicines.
Dr South also highlighted that medication should be part of a broader approach to obesity management, including healthy eating, physical activity, resistance exercise, adequate sleep and psychological support.
Cost remains a major concern
Dr Mark Mellor, Chair of RACGP Specific Interests Obesity Management, said having more treatment options would help doctors provide care that better suits individual patients.
However, he noted that affordability remains a major concern because these medicines are not currently subsidised through the Pharmaceutical Benefits Scheme (PBS).
Dr South also raised concerns about the cost of treatment, saying access should not depend only on what patients can afford.
She added that obesity is a chronic condition and weight regain is common after treatment stops. For this reason, GPs should discuss long-term treatment plans and costs with patients before starting medication.
The injectable form of Wegovy is also not yet listed on the PBS, despite a recommendation for its inclusion by the Pharmaceutical Benefits Advisory Committee almost a year ago.
Novo Nordisk Oceania Senior Director of Medical and Regulatory Dr Ana Svensson said the availability of the tablet in Australia would provide another treatment option for eligible people living with obesity.
Australia’s first oral weight-loss medicine now available through private prescriptions
Source: RACGP newsGP